Text Size

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment.

Geerling, G.; Hamada, S.; Trocmé, S.; Ræder, S.; Chen, X.; Fassari, C.; Lanzl, I.

  • 2022
  • Ophthalmology and therapy
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Department of Ophthalmology, University Hospital Düsseldorf, Düsseldorf, Germany; Queen Victoria Hospital, East Grinstead, UK; Aleris Specialistvård Sabbatsberg, Europakliniken Department of Ophthalmology, Sabbatsbergs Hospital, Stockholm, Sweden; The Norwegian Dry Eye Clinic, Oslo, Norway; Santen SA, Geneva, Switzerland; Chiemsee Augentagesklinik, Prien, Germany

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022